Table 1.
Characteristic | No. | % |
---|---|---|
No. of patients | 23 | |
Median age, year | 61 | |
Range | 22–74 | |
Sex | ||
Male | 14 | 61 |
Female | 9 | 39 |
Performance status | ||
0 | 3 | 13 |
1 | 18 | 78 |
2 | 2 | 9 |
Primary tumor type | ||
Colorectal | 6 | 26 |
Sarcoma | 4 | 17 |
Pancreas | 2 | 9 |
Non-small cell lung | 2 | 9 |
Head and neck | 2 | 9 |
Other** | 7 | 30 |
Prior systemic* therapy | ||
0 | 0 | 0 |
1 | 4 | 17 |
2 | 2 | 9 |
3 | 6 | 26 |
4 | 3 | 13 |
5 | 2 | 9 |
≥6 | 6 | 26 |
Includes conventional chemotherapy, cytokine-based immunotherapy, and experimental cytotoxic chemotherapy.
One each of bladder, gastric, GIST, ovarian, germ cell, mesothelioma and lymphoma.